True North Synergy Inc.

West Vancouver, BC, Canada
Phone: (604) 922-1045
Fax: (604) 922-0282
Email: amancini@truenorthsynergy.com
Biography

As President and Chief Executive Officer of True North Synergy Inc., Alexandra Mancini provides clinical and regulatory consulting services to the pharmaceutical industry based on over 30 years of global drug development experience, including 20 years at the executive level. Alexandra is also a visiting lecturer at the Segal Graduate School of Business, Simon Fraser University.

Most recently, Alexandra was the Senior Vice President of Clinical & Regulatory Affairs at Sirius Genomics of Vancouver, BC from 2008 to 2012. Sirius Genomics was developing a pharmacogenomic biomarker for identification of patients who would respond favourably to a sepsis drug (Xigris®). Sirius was a virtual company with 8 employees and Alexandra identified and managed external resources providing medical expertise in sepsis; clinical data management; statistical theory, programming and analyses; quality assurance; and medical writing.

Prior to joining Sirius Genomics, Alexandra was the Senior Vice President of Clinical & Regulatory Affairs at Inex Pharmaceuticals Corporation of Burnaby, BC from 2001 until June 2005, providing strategic direction and operational management to the business areas of Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance. She led the growth of these areas within the company during the transition from a preclinical research-focused company with approximately 65 employees to one with a late-stage development-focused capability with almost 200 permanent and contract employees.

Prior to joining INEX, Alexandra was Vice President of Regulatory Affairs at QLT PhotoTherapeutics of Vancouver, BC where she worked from 1992 until 1999. While at QLT, she was responsible for the successful regulatory submissions for the drug VISUDYNE® (verteporfin) for the treatment of age-related macular degeneration and for obtaining approvals in several jurisdictions for the anticancer drug PHOTOFRIN® (porfimer sodium) and associated medical devices. Alexandra joined QLT after a decade in the pharmaceutical and food industries, including Parke-Davis Pharmaceutical Research in Ann Arbor, Michigan. Alexandra holds a Master of Science degree from the University of Toronto.

 

Alexandra Mancini

Alexandra Mancini, MSc 
President & Founder